Trial NCT03970837

View at ClinicalTrials.gov 
Org. Study IDs: 201791

Last trial update was posted on 2023-11-30

MeSH Interventions

Tofacitinib

MeSH Conditions

Arthritis Arthritis, Rheumatoid

Other Conditions


Stopping Reasons

Only Asia cohort is early terminated.Limited efficacy demonstrated in the contRAst program does not support a suitable benefit/risk profile for otilimab as a potential treatment for RA. GSK has decided not to progress with regulatory submissions.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID